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In this review, we present 1) scientific basis for the use of high dose immunosuppression
followed by autologous peripheral blood hematopoietic stem cell transplantation for
newly diagnosed type 1 diabetes mellitus, 2) an update of clinical and laboratory outcomes
in 21 patients transplanted at the University Hospital of the Ribeirão Preto Medical
School, University of São Paulo, Brazil, including 6 relapses in patients without previous
ketoacidosis and 3) a discussion of future prospectives of cellular therapy for type 1
diabetes mellitus. Rev. bras. hematol. hemoter. 2008; 30(Supl. 2):55-59.
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Introduction
Based on animal models of autoimmune diseases
successfully treated with high-dose immunosuppression
plus hematopoietic stem cells (autologous or allogeneic)
and on remission of coincidental autoimmune diseases
(AID) in patients treated for hematological disorders
(reviewed in1-4) in 1996 the first patients with isolated AID
were treated with hematopoietic stem cell transplantation
(HSCT). Since then, more than 1,000 patients with severe
and refractory AID have been treated,5 most with autologous
HSCT, because of the lower risk of complications compared
to allogeneic HSCT. Between one to two-thirds of patients
experienced sustained remission of their disease. Relapses
and mortality rates varied with type and status of the disease
and with the intensity of immunosuppression employed pre-
transplant (myeloablative versus nonmyeloablative
conditioning regimens).
Few mechanistic studies performed after HSCT for
AID suggest that the  regenerated immune system is more
tolerant with a regulatory phenotype, marked by increased
numbers of naïve and regulatory T cells and more diverse T
cell receptor repertoire diversity.6,7
Evidence for using hsct in human type 1
diabetes mellitus
After more than ten years of clinical use of HSCT for
severe and refractory AID,  the evidence that this approach
could be beneficial for human type 1 diabetes mellitus
(T1DM) is derived from experimental studies with animal
models of T1DM and from clinical studies using
immunosuppression for early onset DM-1 or in hematopoietic
stem cell transplantation for hematological diseases where
donor or recipient had T1DM (Table 1).
Experimental studies
There are two types of experimental models of auto-
immune diseases, one genetically determined, like the non-
obese diabetic (NOD) and the NZB/W mice, in which AID
develops spontaneously in most animals, and another one
in, like adjuvant arthritis and experimental autoimmune
encephalomyelitis, in which AID is induced by immunization
with the relevant antigen plus Freund adjuvant. The latter
model is considered more relevant to human AID, but no
such model exists for type 1 DM.
In NOD mice, development of clinical overt T1DM is
easily prevented by allogeneic stem cell transplantation, but
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not by autologous HSCT, result that can be anticipated by
the genetic nature of the disease in this model.8 On the other
hand, overt T1DM in NOD mice cannot be reversed by
allogeneic HSCT alone, requiring a source of pancreatic beta-
cells.9 These findings indicate that allogeneic HSC can
reinduce tolerance to pancreatic beta-cells in DM1 but cannot
restore the pool of those cells once it was destroyed by the
autoimmune process.
Immunosuppression for early onset disease
Immune-mediated islet cell destruction is not complete
until sometime after onset of T1DM. This has lead, beginning
in the 1980s, to immunosuppression trials for new onset
T1DM (reviewed in 10,11).  Early diagnosed type I diabetes
patients were treated with prednisone, cyclosporine and/or
azathioprine. Several trials including French, Canadian-
European, Australian, and American indicated that
cyclosporine and/or azathioprine preserved insulin secretion
and/or increased the duration of insulin independence. The
best results seemed to occur for patients with 8 weeks of
T1DM onset. Despite preserving insulin secretion, long term
immunosuppression was impractical due to chronic side
effects. These studies indicate that islet cells persist, at least
for a short time interval of weeks to months after T1DM onset.
Measurements of C-peptide, a marker for endogenous insulin,
indicate persistence of islet cells with low normal C-peptide
levels for 1 year after T1DM onset.
The most encouraging results have been observed
after short-term courses of engineered anti-CD3 monoclonal
antibodies. These studies were pioneered by Eisenbarth et
al12 who induced transient remission (up to 8 months) in a
small group of T1DM treated with prednisone plus
antithymocyte globulin (ATGAM). In one recent study, 12
patients treated with the antibody showed better beta-cell
function and lower insulin dosage after one-year, compared
to the placebo group.13
In a subsequent study with larger number of patients
and extended follow-up, the metabolic (increase in C-peptide
levels) and clinical (decrease in insulin usage) benefits was
maintained up to 2 years after diagnosis.14 However, in neither
study a significant number of patients became insulin free
after immunointervention. In those studies, the long-term
increase of regulatory T cells (Tregs) could be implicated in
prolonged protection (18-24 months) of pancreatic beta-cells
from autoimmune aggression.
Currently, several trials of immunosuppression for early
onset T1DM are being conducted, using polyclonal ATG,
anti-IL2 receptor monoclonal antibody, mycophenolate
mofetil, sirolimus, tacrolimus, anti-CD52 (Campath-1H) or anti-
CD20 (Rituximab) monoclonal antibodies.10
HSCT for hematological diseases where donor
or recipient had type 1 DM
Only one study, from Seattle, investigated the effect of
high dose immunosuppression and HSCT on the metabolic
control of three patients with T1DM transplanted for
hematological diseases (Fanconi anemia, T cell acute
lymphoblastic leukemia or acute myelomonocytic leukemia).15
Two patients received HLA-identical bone marrow
transplantation from family relatives (mother or sister) and
one patient received syngeneic HSCT from an identical twin.
In this study, the long term disease process (3 to 7 years) was
not changed by HSCT, as evaluated by continuous use of
insulin after transplantation. On the other hand, there are few
reports of transference of T1DM from donor to recipient of
allogeneic HSCT for hematological diseases,16 indicating that
HSC may carry disease predisposition in the allogeneic
transplantation setting.
Based on the above discussed evidence, HSCT for early
onset T1DM was proposed in review articles in the literature
in 200117 and 200218 and a cooperative protocol between
Northwestern University in Chicago, USA (Richard Burt) and
University of São Paulo in Ribeirão Preto, Brazil (Júlio Voltarelli
and others) started in Brazil in the end of 2003 after approval
by local and national Institutional Review Boards.
Results of autologous HSCT for newly
diagnosed type 1 diabetes mellitus
Since 2003, our research group in Brazil is conducting
an original study of nonmyeloablative autologous
hematopoietic stem cell transplantation (AHSCT) in patients
with newly diagnosed T1DM.  The objective of the treatment
was to stop autoimmune destruction of ß cells with high-
dose immunosuppressive drugs (cyclophosphamide and
rabbit antithymocyte globulin) and to "reset" the deleterious
immunologic system with a reconstituted one originated from
autologous hematopoietic stem cells.19 The rational is to pre-
serve residual ß cell mass and facilitate endogenous
mechanisms of ß cell regeneration. Hematopoietic stem cells
probably do not have the capacity to differentiate into large
numbers ß cells, therefore these cells are used solely to
regenerate new immune system without autoreactive memory
cells against pancreatic antigens (see below). The exact
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Table 1. Scientific evidence for the possible benefit of high dose
immunosuppression followed by hematopoietic stem cell infusion
in newly diagnosed type 1 diabetes mellitus
Evidence     Ref
Beneficial effects of HSCT for human severe    2-5
autoimmune diseases
Results of HSCT in experimental models of type 1 DM          1, 8-9
Beneficial effects of immunosuppression in                          10-14
human type 1 DM
Lack of benefit of HSCT in long term T1DM                                 15
Transfer of DM1 during HSCT in humans                                    16
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mechanism of action operating in this treatment is
still unclear. However, it has been suggested that
AHSCT may shift the balance from destructive
immunity to immune tolerance through clonal
exhaustion, regulatory cells, cytokine alterations
and changes in T- or B-cell repertoires.1,2
 The procedure of AHSCT comprises several
steps from patient selection through long-term
follow-up. Most patients interested in the study
were excluded for not fulfilling protocol criteria,
especially the short time period (6 weeks) from
diagnosis, occasionally positivity for anti-GAD
antibodies or fully understanding and complying
with the study protocol. Apart from the diabetic
status, all treated patients were in good health status
before transplantation, which explains in part the
low frequency and severity of adverse effects (see
below). This is also explained by the rapid
engraftment of neutrophils (mean of 9 days) and
platelets (mean of 11.4 days).19
The first patient enrolled in December/2003
presented discouraging response. His insulin
requirements increased progressively until 12
months following transplantation (when he
abandoned follow-up) reaching the dose 250%
higher than his initial requirement. His hemoglobin
A1c level was 11.1% at 12 months and his C-
peptide concentration did not increase. The
possible cause for his poor clinical response is
the very low ß cell reserve, predicted by the
previous diagnosis of diabetic ketoacidosis, and
further jeopardized by the ß cell apoptotic effect
of glucocorticoids used  to prevent rabbit
antithymocyte globulin reactions. Considering
these possibilities, we decided not use gluco-
corticoids in the conditioning regimen in the
following patients and did not include those with
previous diabetic ketoacidosis.
At April 2008, after a median follow-up of 28
months (range between 1 to 49 months) all but one
of the subsequent 19 patients became insulin-free,
most of them shortly after starting high dose
immunosuppression, even before stem cell infusion.
Six out of 19 patients resumed insulin use after
transient periods free from insulin ranging from 7 to
48 months (mean 22.4 months) (Figure 1). Five of
them are receiving 30-50% of insulin  doses
compared to the doses used before transplantation
and one patient is using higher doses than pre-
transplantation. Two of these patients resumed insulin use
after an upper respiratory tract infection. The other 13 patients
are continuously insulin-free since insulin suspension: 3
patients for at least 3 years, 4 patients for at least 2 years, 3
patients for at least 1 year and 4 patients for at least 3 months
(Figure 2). The 20th patient did not present any period free
from insulin, but this patient received  steroids (300 mg
hydrocortisone)  along with stem cell infusion to prevent
reactions to DMSO.
There was a statistically significant reduction of mean
hemoglobin A1c concentrations after transplantation. All but
Figure 1. Insulin usage after autologous hematopoietic stem cell transplantation
in 6 type 1 DM patients with transient response. No patient had diabetic
ketoacidosis or used corticosteroids during the transplantation procedure.
Figure 2. Insulin usage after autologous hematopoietic stem cell transplantation
in 13 type 1 DM patients with sustained response. No patient had diabetic
ketoacidosis or used corticosteroids during the transplantation procedure
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2 patients (the 1st and the 11th) presented all measurements
below 7% (upper limit of good glucose control) during follow-
up. As noted above, soon after inclusion, the 1st patient did
not achieve good glucose control. The 11th patient presented
A1c levels < 7% until 12 months after transplantation when
insulin use was restarted and hemoglobin A1c began to
increase.
Regarding the time course of ß cell function, of the
first 14 patients who had C-peptide levels partially analyzed
the majority (n= 11) presented increased values in
comparison with pretreatment levels, indicating preservation
and even improvement of  ß cell function. Analyzing C-
peptide levels during a stimulus with mixed meal tolerance
test, there was a statistically significant increase in mean
area under the curve 6 months after transplantation and
this increase was maintained until 24 months after stem cell
transplantation.19
In face of the good metabolic results presented, the
adverse effects were acceptable. With respect to acute
complications, most patients had febrile neutropenia, nausea,
vomiting and alopecia due to the immunosuppressive agents
used in the mobilization and conditioning phases of the
protocol. Bilateral pneumonia of unidentified etiology that
required supplementary oxygen therapy and responded
completely to broad-spectrum antibiotics occurred in patients
#2 and #21 and they were the only severe acute complications
of the transplantation procedure. During long-term follow-
up, patient 2 presented Graves disease identified 3.5 years
after transplantation, patient 3 developed autoimmune
hypothyroidism and transient renal dysfunction associated
with rhabdomyolysis, a complication that was successfully
treated with levothyroxine. Patient #10 presented mild
transient hypergonadotropic hypogonadism 12 months after
transplantation. These late onset endocrine dysfunctions
presented by these 3 patients can be related to the transplant
procedure itself or to an autoimmune polyendocrine
syndrome frequently associated with T1DM. There was no
mortality.
In July 2007 we initiated a similar study of
nomyeloablative autologous hematopoietic stem cell
transplantation in newly diagnosed individuals with T1DM
who presented previous diabetic ketoacidosis. By January
2008 only one patient had been enrolled in the study and
insulin independence was not achieved, but insulin doses
decreased by less than 40% of the initial requirements.
We are currently performing exhaustive studies of
immunoreconstitution (phenotypic and functional) in the
transplanted patients to unravel the mechanisms by which
AHSCT produces clinical benefit in type 1 diabetic patients.
Preliminary results show that after transplantation, there is
an increase in the numbers of regulatory CD4+CD25+Foxp3+
T cells and Th2 cytokines-producing cells, compared to the
pre-transplant status. In addition, we found after AHSCT
profound qualitative and quantitative changes in TCR
repertoire, as well as alterations in the expression of pro- and
anti-apoptotic genes.20,21 Anti-GAD autoantibodies decreased
in most patients but did not correlate with clinical response.
Our immune reconstitution results are underway and
preliminary results resemble those observed in other
autoimmune diseases after AHSCT.6,7 The results support
the suggested hypothesis that a new and more tolerant
immune system is generated after the treatment, explaining
the reduction of autoimmune destruction and clinical
improvement (Mechanism #2, Table 2). However, in the
presence of anti-GAD autoantibodies and in the absence of
specific immunologic reactivity tests to beta cell antigens,
we cannot be sure that our treatment blocks autoimmune
attack to endocrine pancreas more efficiently and for longer
time than other immunosuppressive interventions,
particularly anti-T cell therapies.
Table 2. Possible mechanisms of action of autologous
hematopoietic stem cell transplantation for
type 1 diabetes mellitus
1. Ablation of autoreactive immune system by high dose
immunosuppression
2. Regeneration of a naïve immune system from autologous
hematopoietic stem cells after lymphoablation by high dose
immunosuppression
3. Regeneration of pancreatic beta-cells from autologous bone
marrow stem cells mobilized to the peripheral blood
Conclusions and prospectives
Our preliminary study of autologous HSCT in a subset
of non-ketoacidotic newly diagnosed type 1 DM patients
yield unexpected positive results: 19/20 patients could stop
insulin use after initiation of high dose immunosuppression
and 16 patients maintained this status after a median follow-
up of almost two years (maximum of 4 years). Six patients
relapsed after stopping insulin use and one patient who
received steroids during conditioning never discontinued
insulin. Longer follow-up and controlled studies are certainly
needed to evaluate the full potential of the procedure in the
reversion of type 1 DM.
The underlying mechanism of action of the various
components of the AHSCT (cyclophosphamide, ATG and
stem cells) cannot be studied by direct methods in humans,
but our immune reconstitution study which is currently
underway and similar studies in other AIDs suggest that the
immune system is reset towards a tolerant phenotype by
increased regulatory T cell numbers and by regeneration of a
different and more diverse TCR repertoire. We hypothesize
that the combination of high dose immunosuppression and
hematopoietic stem cell infusion act synergistically to
downregulate the autoreactive cells, to renew the immune
system and to improve the immune regulatory networks.
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While our approach provides the proof of principle that
high dose immunosuppression coupled with autologous
hematopoietic stem cell boosting can revert clinical type 1 DM
in humans, it will hardly solve the problem of the disease.
Firstly, only a small subset of patients were successfully treated
with AHSCT, millions of patients with long standing type 1
DM need another source of stem cells to regenerate pancreatic
beta-cells and other damaged tissues. Secondly, AHSCT is an
expensive, cumbersome and complex procedure performed in
specialized bone marrow transplantation facilities and has the
potential of life threatening short and long term complications.
In the future, more simple approaches such as chemical,
biological or cellular immunoregulatory interventions may
accomplish the same therapeutic goal and may be applied to
millions of type 1 diabetic patients who need a definitive
treatment. In the meanwhile, AHSCT remains the only treatment
to reverse the disease in humans and has to be tested in other
groups of patients (with previous ketoacidosis, with longer
duration of the disease and in young children).
Resumo
Nesta revisão, são apresentadas: 1) as bases científicas para o uso
de imunossupressão em alta dose seguida de transplante autólogo
de células-tronco hematopoéticas do sangue periférico no diabete
melito do tipo 1 recém-diagnosticado; 2) uma atualização da evolu-
ção clínica e laboratorial de 21 pacientes transplantados no Hospi-
tal das Clínicas da Faculdade de Medicina de Ribeirão Preto, da
Universidade de São Paulo, Brasil, incluindo recaídas em seis pa-
cientes transplantados sem cetoacidose prévia; e 3) uma discussão
das perspectivas futuras de terapia celular no diabete melito do tipo
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Palavras-chave: Diabete melito; terapia celular; transplante de
células-tronco hematopoéticas.
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